Downregulation of PARD6B Is Associated with Irreversible Podocyte Damage in FSGS

Background: Focal segmental glomerulosclerosis (FSGS) often presents treatment resistance, necessitating further elucidation of its pathophysiology. Podocytes, the glomerular epithelial cells, maintain homeostasis through polarity regulation, but the role of polarity-related factors in FSGS remains poorly understood. We analyzed the expression of polarity-related factors in isolated glomeruli from human FSGS using Nephroseq, an omics analysis database for kidney diseases. As a result, we found that PARD6B was significantly downregulated in FSGS compared to normal controls, along with CRB2, which is a causative gene for hereditary FSGS. Since PARD6B is mainly expressed in podocytes within the glomerulus, this suggests a potential association with podocyte injury. This study aims to investigate the functional role of PARD6B in the pathogenesis of FSGS. Methods: We evaluated PARD6B expression in isolated glomeruli from podocyte injury mouse models induced by adriamycin or LPS. Tamoxifen-inducible podocyte-specific PARD6B-deficient mice were generated, and urine protein and renal pathology were assessed. In vitro functional analyses were performed using human podocyte cell lines treated with TNF-α or PARD6B siRNA. Results: Glomeruli isolated from podocyte-damaged mouse models exhibited significantly reduced PARD6B expression. Tamoxifen-induced podocyte-specific PARD6B-deficient mice showed severe proteinuria, podocyte swelling, epithelial cell hyperplasia, segmental sclerosis, and diffuse epithelial cell foot processes effacement, resembling human FSGS. Reduced nephrin expression/ abnormal localization and increased detached podocytes were also observed. In vitro, TNFα-treated human podocytes displayed significantly reduced PARD6B expression. Human podocytes treated with PARD6B siRNA demonstrated significant cell death, though no effects on the actin cytoskeleton were noted. Conclusion: These findings suggest that reduced PARD6B expression is associated with irreversible podocyte injury and progression of FSGS. Funding: Private Foundation Support

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2025-10-01
DOI
https://doi.org/10.1681/asn.2025bse44br1
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Downregulation of PARD6B Is Associated with Irreversible Podocyte Damage in FSGS

Tomoki Kosugi, Yuka Sato, Shoichi Maruyama, Katsuaki Shibata et al.
Journal of the American Society of Nephrology
Renal Diseases and Glomerulopathies
article

Downregulation of PARD6B Is Associated with Irreversible Podocyte Damage in FSGS

Tomoki Kosugi, Yuka Sato, Shoichi Maruyama, Katsuaki Shibata, Noritoshi Kato, Kayaho Maeda
article en

Abstract

Background: Focal segmental glomerulosclerosis (FSGS) often presents treatment resistance, necessitating further elucidation of its pathophysiology. Podocytes, the glomerular epithelial cells, maintain homeostasis through polarity regulation, but the role of polarity-related factors in FSGS remains poorly understood. We analyzed the expression of polarity-related factors in isolated glomeruli from human FSGS using Nephroseq, an omics analysis database for kidney diseases. As a result, we found that PARD6B was significantly downregulated in FSGS compared to normal controls, along with CRB2, which is a causative gene for hereditary FSGS. Since PARD6B is mainly expressed in podocytes within the glomerulus, this suggests a potential association with podocyte injury. This study aims to investigate the functional role of PARD6B in the pathogenesis of FSGS. Methods: We evaluated PARD6B expression in isolated glomeruli from podocyte injury mouse models induced by adriamycin or LPS. Tamoxifen-inducible podocyte-specific PARD6B-deficient mice were generated, and urine protein and renal pathology were assessed. In vitro functional analyses were performed using human podocyte cell lines treated with TNF-α or PARD6B siRNA. Results: Glomeruli isolated from podocyte-damaged mouse models exhibited significantly reduced PARD6B expression. Tamoxifen-induced podocyte-specific PARD6B-deficient mice showed severe proteinuria, podocyte swelling, epithelial cell hyperplasia, segmental sclerosis, and diffuse epithelial cell foot processes effacement, resembling human FSGS. Reduced nephrin expression/ abnormal localization and increased detached podocytes were also observed. In vitro, TNFα-treated human podocytes displayed significantly reduced PARD6B expression. Human podocytes treated with PARD6B siRNA demonstrated significant cell death, though no effects on the actin cytoskeleton were noted. Conclusion: These findings suggest that reduced PARD6B expression is associated with irreversible podocyte injury and progression of FSGS. Funding: Private Foundation Support

Journal of the American Society of NephrologyVol. 36(10S)
Nagoya University (JP)
Openalex Percentile: Top 53%
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.